Last reviewed · How we verify
GRF6019
At a glance
| Generic name | GRF6019 |
|---|---|
| Sponsor | Alkahest, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease (PHASE2)
- A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRF6019 CI brief — competitive landscape report
- GRF6019 updates RSS · CI watch RSS
- Alkahest, Inc. portfolio CI